A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

NCT07535112 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastatic Colorectal Adenocarcinoma

Interventions

DRUG: BAY 3771249
DRUG: Cetuximab

Sponsor

Bayer